Rabies infection (RABV), logical name Rabies lyssavirus, is a dangerous neurotropic infection that causes rabies in people and creatures. Rabies infection has a very wide host range and its transmission most frequently happen through the salivation of creatures. Without mediation preceding illness movement, rabies has the most noteworthy case casualty of any irresistible infection.
RABV contains a solitary abandoned negative-sense RNA genome that encodes five primary proteins: nucleoprotein (N), phosphoprotein (P), network protein (M), glycoprotein (G), and RNA-subordinate RNA polymerase (L). Among these viral proteins, the RABV glycoprotein (RABV-G) is a vital player interceding infection passage and the significant objective of killing antibodies, accordingly a critical component for immunization and medication plan.
SARS-CoV-2 Spike Glycoprotein (Trimeric), His-Tag (CHO)
SARS-CoV-2 trimeric spike glycoprotein is produced in CHO cells to high return and immaculateness. Protein has proline replacements at deposits 986 and 987, a GSAS replacement at the furin cleavage site (buildups 682-685), and a C-terminal His-tag. HRP formed protein additionally accessible. SARS-CoV-2, recently known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 sickness.
SARS-CoV-2 Spike Glycoprotein (Full-Length), His-Tag (CHO)
Recombinant full-length SARS-CoV-2 spike glycoprotein, produced in Chinese hamster ovary (CHO) cells to high return and immaculateness. The furin cleavage site (amino acids 682-685) has been transformed from RRAR to SRAS and the transmembrane area and intravirion part supplanted with a glycine-serine linker and a His-tag. Horseradish peroxidase formed protein additionally accessible. SARS-CoV-2, recently known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 sickness.
SARS-CoV-2 Trimeric spike CHO
Trimeric SARS-CoV-2 spike protein in prefusion affirmation. C-terminal transmembrane area is supplanted with a trimerization space and a polyhistidine tag. Contains two balancing out proline changes and mixed S1/S2 furin cleavage site (Wrapp et al.
Undeniable level articulation of the monomeric SARS-CoV-2 S protein RBD 320-537 in steadily transfected CHO cells by the EEF1A1-based plasmid vector
The spike (S) protein is one of the three proteins shaping the Covids’ viral envelope. The S protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has a spatial design like the S proteins of other mammalian Covids, with the exception of a novel receptor-restricting area (RBD), which is a critical inducer of host insusceptible reaction. Recombinant SARS-CoV-2 RBD is broadly utilized as a profoundly unambiguous negligible antigen for serological tests.
Right openness of antigenic determinants fundamentally affects the precision of such tests-the antigen must be accurately collapsed, contain no possibly antigenic non-vertebrate glycans, and, ideally, ought to have a glycosylation design like the local S protein. In view of the recently evolved p1.1 vector, containing the administrative successions of the Eukaryotic interpretation extension factor 1 alpha quality (EEF1A1) from Chinese hamster, we made two articulation builds encoding SARS-CoV-2 RBD with C-terminal c-myc and polyhistidine labels. RBDv1 contained a local viral sign peptide, RBDv2 – human tPA signal peptide. We transfected a CHO DG44 cell line, chose steadily transfected cells, and played out a couple of rounds of methotrexate-driven intensification of the hereditary tape in the genome.
Spike (SARS-CoV-2) Lentivirus | ||||
| 78010-2 | BPS Bioscience | 500 µl x 2 | 2095 EUR | |
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial | ||||
| E80028 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag | ||||
| E80024 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion | ||||
| E80026 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag | ||||
| E80025 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag | ||||
| E80021 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag | ||||
| E80023 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag | ||||
| E80020 | EpiGentek |
|
|
|
SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag | ||||
| E80022 | EpiGentek |
|
|
|
Spike S1, Fc fusion (SARS-CoV-2) | ||||
| 100688-2 | BPS Bioscience | 50 µg | 505 EUR | |
Anti-Spike S1 Antibody (SARS-CoV-2) | ||||
| 100715-2 | BPS Bioscience | 100 µg | 440 EUR | |
Spike S2, Fc-Tag (SARS-CoV-2) | ||||
| 100895-2 | BPS Bioscience | 500 µg_x000D_ | 1815 EUR | |
Spike S1 RBD, His-tag (SARS-CoV-2) | ||||
| 100687-2 | BPS Bioscience | 100 µg | 520 EUR | |
Spike S1 RBD, Fc fusion (SARS-CoV-2) | ||||
| 100699-2 | BPS Bioscience | 100 µg | 520 EUR | |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) | ||||
| 79942-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR | |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) | ||||
| 79981-2 | BPS Bioscience | 500 µl x 2 | 5245 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant | ||||
| P1530-10 | Biovision | 10 µg | 187.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant | ||||
| P1530-50 | Biovision | 50 µg | 709.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant | ||||
| P1531-10 | Biovision | 10 µg | 235.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant | ||||
| P1531-50 | Biovision | 50 µg | 709.2 EUR | |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2), Recombinant | ||||
| P1547-10 | Biovision | 10 μg | 235.2 EUR | |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2), Recombinant | ||||
| P1547-50 | Biovision | 50 μg | 782.4 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant | ||||
| P1555-10 | Biovision | 10μg | 235.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant | ||||
| P1555-50 | Biovision | 50μg | 709.2 EUR | |
Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2) | ||||
| 100938-2 | BPS Bioscience | 50 µg | 555 EUR | |
SARS-CoV Spike Protein | ||||
| abx060655-1mg | Abbexa | 1 mg | 2030.4 EUR | |
SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag | ||||
| E80027 | EpiGentek |
|
|
|
SARS-CoV-2 Spike Peptide | ||||
| 9083P | ProSci | 0.05 mg | 235.5 EUR | |
SARS-CoV-2 Spike Peptide | ||||
| 9087P | ProSci | 0.05 mg | 235.5 EUR | |
SARS-CoV-2 Spike Peptide | ||||
| 9091P | ProSci | 0.05 mg | 235.5 EUR | |
SARS-CoV-2 Spike Peptide | ||||
| 9095P | ProSci | 0.05 mg | 235.5 EUR | |
Spike (SARS-CoV-2) Lentivirus | ||||
| 78010-1 | BPS Bioscience | 100 µl | 835 EUR | |
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial | ||||
| E80028-2 | EpiGentek | 100 ul | 860.2 EUR | |
Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2) | ||||
| 100684-2 | BPS Bioscience | 50 µg | 435 EUR | |
Spike S1 RBD, Avi-His-tag (SARS-CoV-2) | ||||
| 100696-2 | BPS Bioscience | 1 mg | 3200 EUR | |
Spike Trimer (S1+S2), His-tag (SARS-CoV-2) | ||||
| 100728-2 | BPS Bioscience | 1 mg | 2995 EUR | |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) | ||||
| 78028-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR | |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter) | ||||
| 78035-2 | BPS Bioscience | 500 µl x 2 | 5145 EUR | |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag | ||||
| E80024-2 | EpiGentek | 1 ml | 4995.1 EUR | |
SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion | ||||
| E80026-2 | EpiGentek | 50 ul | 823.9 EUR | |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S1), Recombinant | ||||
| P1524-10 | Biovision | 10 µg | 332.4 EUR | |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S2), Recombinant | ||||
| P1525-10 | Biovision | 10 µg | 332.4 EUR | |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant | ||||
| P1529-10 | Biovision | 10 µg | 235.2 EUR | |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant | ||||
| P1529-50 | Biovision | 50 µg | 709.2 EUR | |
SARS-CoV Spike Antibody | ||||
| 3219-002mg | ProSci | 0.02 mg | 206.18 EUR | |
SARS-CoV Spike Antibody | ||||
| 3219-01mg | ProSci | 0.1 mg | 523.7 EUR | |
SARS-CoV Spike Antibody | ||||
| 3221-002mg | ProSci | 0.02 mg | 206.18 EUR | |
SARS-CoV Spike Antibody | ||||
| 3221-01mg | ProSci | 0.1 mg | 523.7 EUR | |
SARS-CoV Spike Antibody | ||||
| 3223-002mg | ProSci | 0.02 mg | 206.18 EUR | |
SARS-CoV Spike Antibody | ||||
| 3223-01mg | ProSci | 0.1 mg | 523.7 EUR | |
SARS-CoV Spike Antibody | ||||
| 3225-002mg | ProSci | 0.02 mg | 206.18 EUR | |
SARS-CoV Spike Antibody | ||||
| 3225-01mg | ProSci | 0.1 mg | 523.7 EUR | |
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag | ||||
| E80025-2 | EpiGentek | 1 ml | 3934.7 EUR | |
Spike Trimer (S1+S2), His-tag (SARS-CoV) | ||||
| 100789-2 | BPS Bioscience | 500 µg_x000D_ | 1900 EUR | |
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) | ||||
| 78614-2 | BPS Bioscience | 500 µl x 2 | 4320 EUR | |
SARS-CoV spike protein Antibody | ||||
| abx023139-100ug | Abbexa | 100 ug | 1028.4 EUR | |
SARS-CoV spike protein Antibody | ||||
| abx023143-100ug | Abbexa | 100 ug | 1028.4 EUR | |
Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2) | ||||
| 100698-2 | BPS Bioscience | 1 mg | 2500 EUR | |
Spike S1 (16-685), Avi-His-tag (SARS-CoV-2) | ||||
| 100730-2 | BPS Bioscience | 1 mg | 2720 EUR | |
Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2) | ||||
| 100769-2 | BPS Bioscience | 1 mg | 2500 EUR | |
Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2) | ||||
| 100846-2 | BPS Bioscience | 1 mg | 2600 EUR | |
Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2) | ||||
| 100992-2 | BPS Bioscience | 1 mg | 2850 EUR | |
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) | ||||
| 78112-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR | |
Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) | ||||
| 78637-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR | |
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) | ||||
| 79982-2 | BPS Bioscience | 500 µl x 2 | 8110 EUR | |
SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag | ||||
| E80021-2 | EpiGentek | 1 ml | 4276.8 EUR | |
SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag | ||||
| E80023-2 | EpiGentek | 1 ml | 3934.7 EUR | |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate | ||||
| 79952-2 | BPS Bioscience | 10 mg | 3460 EUR | |
SARS-CoV-2 Spike S2 Peptide | ||||
| 9119P | ProSci | 0.05 mg | 235.5 EUR | |
SARS-CoV-2 Spike S2 Peptide | ||||
| 9123P | ProSci | 0.05 mg | 235.5 EUR | |
SARS-CoV-2 Spike Monoclonal Antibody | ||||
| A73664-050 | EpiGentek | 50 ul | 341 EUR | |
SARS-CoV-2 Spike Monoclonal Antibody | ||||
| A73664-100 | EpiGentek | 100 ul | 518.1 EUR | |
SARS-CoV-2 Spike RBD Nanobody | ||||
| A73680-050 | EpiGentek | 50 ul | Ask for price | |
SARS-CoV-2 Spike RBD Nanobody | ||||
| A73680-100 | EpiGentek | 100 ul | 882.2 EUR | |
SARS-CoV-2 Spike Monoclonal Antibody | ||||
| A73664 | EpiGentek |
|
|
|
SARS-CoV-2 Spike RBD Nanobody | ||||
| A73680 | EpiGentek |
|
|
|
Human CellExp™ SARS-CoV-2 Spike Protein (S1; His-tag), Recombinant | ||||
| P1532-10 | Biovision | 10 µg | 187.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (S1; His-tag), Recombinant | ||||
| P1532-50 | Biovision | 50 µg | 661.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD 310-568), Recombinant | ||||
| P1543-10 | Biovision | 10 µg | 187.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD 310-568), Recombinant | ||||
| P1543-50 | Biovision | 50 µg | 576 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD; 331-524), Recombinant | ||||
| P1544-10 | Biovision | 10 µg | 187.2 EUR | |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD; 331-524), Recombinant | ||||
| P1544-50 | Biovision | 50 µg | 576 EUR | |
SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag | ||||
| E80020-2 | EpiGentek | 1 ml | 4276.8 EUR | |
SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag | ||||
| E80022-2 | EpiGentek | 1 ml | 4276.8 EUR | |
For the RBDv2 variation, a high return clonal maker cell line was gotten. We fostered a straightforward purging plan that reliably yielded up to 30 mg of RBD protein per liter of the basic shake flagon cell culture. Cleaned proteins were dissected by polyacrylamide gel electrophoresis in lessening and non-diminishing circumstances and gel filtration; for RBDv2 protein, the monomeric structure content surpassed 90% for a very long time. Deglycosylation with PNGase F and mass spectrometry affirmed the presence of N-glycosylation. The antigen delivered by the depicted procedure is reasonable for serological tests and subunit immunization review.